Abstract
Abstract

Introduction
Gene expression profiling has consistently identified three molecular subtypes of lung adenocarcinoma that have prognostic implications. To facilitate stratification of patients with this disease into similar molecular subtypes, we developed and validated a simple, mutually exclusive classification.
Methods
Mutational status of EGFR, KRAS, and TP53 was used to define six mutually exclusive molecular subtypes. A development cohort of 283 cytology specimens of lung adenocarcinoma was used to evaluate the associations between the proposed classification and clinicopathologic variables including demographic characteristics, smoking history, fluorescence in situ hybridization and molecular results. For validation and prognostic assessment, 63 of the 283 cytology specimens with available survival data were combined with a separate cohort of 428 surgical pathology specimens of lung adenocarcinoma.
Results
The proposed classification yielded significant associations between these molecular subtypes and clinical and prognostic features. We found better overall survival in patients who underwent surgery and had tumors enriched for EGFR mutations. Worse overall survival was associated with older age, stage IV disease, and tumors with comutations in KRAS and TP53. Interestingly, neither chemotherapy nor radiation therapy showed benefit to overall survival.
Conclusions Introduction
Lung cancer is the main cause of cancer-related mortality in both men and women [1] [2] [3] . Lung adenocarcinoma accounts for approximately 40% of lung cancer cases [4] [5] [6] . Gene expression profiling (GEP) of lung adenocarcinomas has consistently identified three molecular subtypes with prognostic implications [7] [8] [9] [10] [11] [12] [13] [14] . The initial molecular classification of lung adenocarcinomas included the bronchoid, magnoid, and squamoid subtypes 11, 15 . However, after comprehensive molecular profiling of a cohort of lung adenocarcinomas, The Cancer Genome Atlas Research Network proposed an updated nomenclature for this molecular classification that encompasses previous histopathologic, anatomic, and mutational classifications 13 . This system re-designated the initial subtypes as the terminal respiratory unit, proximal-proliferative, and proximalinflammatory subtypes, respectively 13 .
Tumors with acinar, papillary, or lepidic histomorphology and mutations or copy number alterations in EGFR, presenting most often in women who have never smoked, predominantly cluster in the terminal respiratory unit subtype. Tumors in the proximalproliferative subtype have variable histology and commonly display mutations and copy number alterations in KRAS and STK11. In contrast, lung adenocarcinomas with primarily solid architecture and enrichment for TP53 and NF1 mutations and p16 methylation typically cluster in the proximal-inflammatory subtype 13, 15 . While molecular subtypes of lung adenocarcinoma have been associated with significant differences in prognosis, routine GEP in the clinical setting has been limited by cost, complexity, and increased turnaround time 16 . These limitations have led to the development of simplified prognostic models based on the expression of selected genes 10, 16 . However, many of these genes, such as PTK7, CIT, SCNN1A, PTGES,   ERO1A, ZWINT, DUSP6, MMD, STAT1, ERBB3, and LCK, are not tested routinely in the clinical laboratory.
To fill this need, we developed a simplified molecular subtype classification based on the mutational status of only EGFR, KRAS, and TP53 to facilitate categorization of patients' lung adenocarcinomas into molecular subtypes with relevant prognostic information.
Materials and Methods
Patient selection for development cohort
We retrospectively reviewed our institutional database for patients treated between May 1, 2010, and October 31, 2015, to identify cytologic specimens of patients with lung adenocarcinoma. Patients with TTF1-negative non-small cell lung cancer, small cell lung cancer, large cell carcinoma, squamous carcinoma, and poorly differentiated carcinoma not otherwise specified were excluded. We reviewed the patients' medical records for demographic characteristics, clinical information, fluorescence in situ hybridization (FISH) results for ALK, ROS1, MET, and/or RET, and mutation profiling data derived by next-generation sequencing (NGS) and polymerase chain reaction (PCR)-based methods (i.e. Sanger sequencing or pyrosequencing).
PCR-based methods were restricted to analysis of only EGFR, KRAS, and BRAF hotspots.
Patient selection for validation cohort
Patients from our institution's Genomic Marker-Guided Therapy Initiative (GEMINI) project database were selected as a validation cohort. This group included patients who underwent computerized tomography-guided transthoracic core-needle biopsy for diagnosis and/or staging of lung adenocarcinomas as well as patients who underwent surgery to resect lung adenocarcinoma between November 1, 2009, and October 31, 2016. Age, sex, race/ethnicity, smoking status, NGS mutation data, survival status, and treatment information were included in the analysis. To avoid Simpson's paradox 17 , we combined this cohort with a subset of cytology cases from the development cohort whose medical record numbers matched to those of records in the GEMINI database and who had available survival information and treatment data.
Mutational analysis
NGS was performed on cytology smears or formalin-fixed paraffin-embedded tissue (cytology cell blocks or core biopsy tissue blocks) using the Ion Torrent or Ion Proton (Thermo Fisher Scientific) sequencers in our College of American Pathologistsaccredited, Clinical Laboratory Improvement Amendments-certified laboratory. Multiple NGS panels were developed, validated, and implemented in our laboratory during the study period (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) classified as the non-TRUPPPI subtype, and a few cases that lacked mutations in any of the genes detected by our NGS panels were placed in a "no-mutation" subtype.
Statistical Methods
Development cohort
Categorical variables were summarized by frequencies and percentages, and continuous variables were summarized using means, standard deviations, medians, and ranges. Fisher exact test or its generalization for categorical variables was used to compare categorical variables between molecular subtypes; in addition, Monte Carlo simulation approach was used when computational issues were encountered. Patients with indeterminate FISH results or unknown aneuploidy status were excluded from the Fisher exact tests. The Wilcoxon rank sum test or Kruskal-Wallis rank-sum test was used to compare continuous variables between molecular subtypes.
Validation cohort
Associations between variables and subtypes were assessed as described for the development cohort. The outcome variable of overall survival (OS) time was computed from the date of initial diagnosis to the last follow-up date or death date. For the subset of patients who had surgery, separate analyses were performed of OS from the date of surgery. Cox proportional hazards models were used to evaluate associations of variables with survival outcomes, and Firth penalized Cox regression models were fitted for covariates with zero count of events. In multivariate Cox regression analyses, we included covariates that had p values less than 0.25 in univariate Cox regression models. Treatment variables (surgery, radiation, and chemotherapy) were handled as time-varying covariates. The Kaplan-Meier method was used to estimate survival distributions, and the log-rank test was used for comparisons between survival distributions. All statistical analyses were performed using R version 3.3.11 21 and SAS version 9.4. All statistical tests used a significance level of 5%, and no adjustments for multiple testing were made.
Results
Development cohort
We collected a development cohort of 283 consecutive cytology samples from patients with lung adenocarcinoma. The samples were acquired via endobronchial 
Validation cohort
To validate these findings and determine the impact of our subtypes on prognosis, we used a validation cohort (n=428) composed of core-needle biopsy samples or resection specimens from lung adenocarcinoma patients with available data on treatment and follow-up. Histomorphologic subtypes (e.g., mucinous, lepidic, acinar, and solid) were reported in 28.3% (n=121) of the pathology reports. The mutational data for this cohort were based only on NGS because all three target genes were not assessed in cases where PCR-based single-gene analysis was performed. Also, we included the 63 patients from the cytology cohort in the GEMINI database with treatment and follow-up data available. NGS results were available for 85.7% (n=54) of these cases.
Mutational profiling of lung adenocarcinoma patients in the validation cohort
Sequencing data were available for 484 (98.6%) patients in the combined validation cohort. NGS and PCR analyses yielded a total of 835 mutations/variants in 421 patients (87.0%). The median tumor percentage was 40% (range: 20 to 95 % tumor cells). Most of the genomic alterations were missense mutations (75%, n=618), followed by in-frame deletions (7%, n=58), nonsense (6.6%, n=55) and frameshift (5%, n=40) mutations, duplications (2.1%, n=18), complex mutations/indels (1.8%, n=15), splice mutations (1.4%, n=12), and gene amplifications (1.1%, n=10). Transversions included G>T (27%, n=222), T>G (7%, n=60), C>A (1.5%, n=13), and A>C (1%, n=8), and transitions included G>A (13%, n=106), C>T (12%, n=99), A>G (4%, n=34), and T>C (1%, n=9). The most common protein alterations were KRAS-G12C (n=58), EGFR-
and EGFR-T790M (n=27). The mutational data for all 491 cases in the validation cohort, stratified by simplified molecular subtype, are summarized in Figure 1 .
Clinical and histomorphologic associations according to simplified molecular subtypes
The simplified molecular subtypes were significantly associated with age, race/ethnicity, sex, smoking status, stage, histomorphology and FISH results ( Table 3) .
As in the development cohort, variables were compared between patients within a given molecular subtype and the remaining patients. were identified between subtype and alcohol intake.
Prognostic associations according to simplified molecular subtype classification
We assessed overall survival in the validation cohort as previously described.
The median follow-up time was 1.87 years (interquartile range: 0.9-3.5 years Figure 3A shows significant differences in OS within this subset of patients. We observed statistically significant differences in OS between the sTRU, sPP, and sPI subtypes ( Figure 3B ), however, differences between these subtypes when categorized in early stages I and II or late stages III and IV did not reach statistical significance (not shown). Interestingly, when compared with patients who underwent surgery, no significant differences in OS were observed in patients who received chemotherapy, and OS was significantly worse in those who received radiation therapy, regardless of molecular subtype (HR=1.87, 95% CI: 1.18-2.96, p=0.007).
Notably, OS did not significantly differ between the sTRU and EGFR/TP53 subtypes (log-rank test p=0.84), either in all patients (not shown) or in the patients who underwent surgery ( Figure 3C ), suggesting that these subtypes could represent a single group.
Conversely, the KRAS/TP53 subtype showed the poorest OS both among all patients (HR=2.15, 95% CI: 1.02-4.53, p=0.043) ( Figure 2B ) and among those who underwent surgery (HR=1.935, 95% CI: 0.923-4.058) ( Figure 3D ).
Discussion
In this study, we show that the mutational status of three commonly mutated genes can be utilized to create a simplified, mutually exclusive molecular subtype classification of lung adenocarcinomas based on molecular subtypes previously identified using GEP or larger gene mutation panels and that this simplified classification shows a relationship with prognosis, especially in patients who have undergone surgery. .
Others have shown that GEP using microarray technology reliably estimates prognosis 10, 16 , but the use of microarrays in the clinical setting is limited by the large number of analyzed genes, complex methods, independent validation of the results, low inter-laboratory reproducibility, high cost, long turnaround time, and the need for fresh or frozen tissue 40 . By creating mutually exclusive groups based on easily accessible data, such as EGFR, KRAS, and TP53 status, the classification of lung adenocarcinomas into prognostic molecular subtypes could become readily available in routine clinical practice. While oversimplification is a potential limitation of the classification proposed, we believe this simplified classification provides useful prognostic information while retaining the updated proposed nomenclature (i.e., TRU, PP, and PI). This simplified approach will make it easier for molecular genetics laboratories and clinicians to accurately classify patients and will help maintain consistency across different molecular laboratories employing NGS platforms for genomic analysis. Because of the increasing demand for multigene testing over single-gene tests 39 and because most, available NGS panels testing lung adenocarcinoma samples contain these three key genes, we suggest that this simplified classification be used primarily for results obtained via NGS.
In summary, using mutational data for EGFR, KRAS, and TP53, we have defined prognostic groups similar to those previously identified by more complex genomic methods in patients with lung adenocarcinomas.
18 Table 3 . Associations between molecular subtypes and clinicopathologic variables in the validation cohort. 
